Bio-Rad Laboratories Stock Price, News & Analysis (NYSE:BIO)

$254.65 0.11 (0.04 %)
(As of 01/23/2018 04:52 AM ET)
Previous Close$254.54
Today's Range$250.95 - $255.80
52-Week Range$183.43 - $273.87
Volume134,700 shs
Average Volume175,036 shs
Market Capitalization$7.58 billion
P/E Ratio322.34
Dividend YieldN/A
Beta0.97

About Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:BIO
CUSIP09057220
Phone510-724-7000

Debt

Debt-to-Equity Ratio0.15%
Current Ratio4.06%
Quick Ratio2.77%

Price-To-Earnings

Trailing P/E Ratio322.341772151899
Forward P/E Ratio95.02
P/E Growth2.06

Sales & Book Value

Annual Sales$2.07 billion
Price / Sales3.66
Cash Flow$3.87 per share
Price / Cash65.74
Book Value$87.46 per share
Price / Book2.91

Profitability

Trailing EPS$0.79
Net Income$28.12 million
Net Margins1.15%
Return on Equity3.44%
Return on Assets2.34%

Miscellaneous

Employees8,250
Outstanding Shares29,760,000

Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories declared that its board has approved a stock repurchase program on Wednesday, November 29th 2017, which permits the company to buyback $250,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its quarterly earnings results on Thursday, November, 2nd. The medical research company reported $0.91 EPS for the quarter, topping the Zacks' consensus estimate of $0.54 by $0.37. The medical research company earned $535 million during the quarter, compared to the consensus estimate of $507.99 million. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. Bio-Rad Laboratories's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm posted $0.62 earnings per share. View Bio-Rad Laboratories' Earnings History.

When will Bio-Rad Laboratories make its next earnings announcement?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Bio-Rad Laboratories.

Where is Bio-Rad Laboratories' stock going? Where will Bio-Rad Laboratories' stock price be in 2018?

3 brokerages have issued 12-month price objectives for Bio-Rad Laboratories' shares. Their predictions range from $255.00 to $290.00. On average, they anticipate Bio-Rad Laboratories' stock price to reach $273.33 in the next year. View Analyst Ratings for Bio-Rad Laboratories.

What are Wall Street analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:

  • 1. According to Zacks Investment Research, "Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. " (12/13/2017)
  • 2. Jefferies Group LLC analysts commented, "Time to forget everything you thought you knew about BIO -- as two separate updates y'day included several "firsts" that add conviction to our bullish thesis: 1) 2020 rev & margin goals; 2) capital allocation plan opens the door for buybacks; 3) board shuffle / quality upgrade. Bottom line: the pathway to $300+ in 2-3 yrs just got a lot clearer & BIO's new shareholder-friendly behavior eliminates the rationale for a structural valuation discount, in our view." (3/14/2017)

Who are some of Bio-Rad Laboratories' key competitors?

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:

  • Norman D. Schwartz, Chairman of the Board, President, Chief Executive Officer (Age 71)
  • Christine A. Tsingos, Chief Financial Officer, Executive Vice President (Age 59)
  • John P. Goetz, Chief Operating Officer, Executive Vice President (Age 67)
  • Timothy Scott Ernst, Executive Vice President, General Counsel and Secretary (Age 57)
  • Michael Crowley, Executive Vice President, Global Commercial Operations (Age 55)
  • Shannon Hall, Executive Vice President, President, Life Science Group (Age 47)
  • John Hertia, Executive Vice President, President, Clinical Diagnostics Group (Age 61)
  • Giovanni Magni, Executive Vice President, Chief Strategy Officer (Age 60)
  • Ronald W. Hutton, Vice President, Treasurer (Age 59)
  • Alice N. Schwartz, Director (Age 90)

Who owns Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (2.80%), Schwab Charles Investment Management Inc. (0.41%), Winslow Asset Management Inc. (0.09%), Bank of Montreal Can (0.06%), Louisiana State Employees Retirement System (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Bio-Rad Laboratories stock include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories.

Who sold Bio-Rad Laboratories stock? Who is selling Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Oakbrook Investments LLC and Louisiana State Employees Retirement System. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories.

Who bought Bio-Rad Laboratories stock? Who is buying Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Bank of Montreal Can, State of Alaska Department of Revenue, Wealth Enhancement Advisory Services LLC and Winslow Asset Management Inc.. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy Bio-Rad Laboratories stock?

Shares of Bio-Rad Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of Bio-Rad Laboratories stock can currently be purchased for approximately $254.65.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $7.58 billion and generates $2.07 billion in revenue each year. The medical research company earns $28.12 million in net income (profit) each year or $0.79 on an earnings per share basis. Bio-Rad Laboratories employs 8,250 workers across the globe.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (BIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bio-Rad Laboratories (NYSE:BIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $273.33$273.33$260.00$225.00
Price Target Upside: 3.81% upside3.81% upside13.25% upside2.75% downside

Bio-Rad Laboratories (NYSE:BIO) Consensus Price Target History

Price Target History for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE:BIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017Wells Fargo & CoReiterated RatingOutperform$250.00 -> $290.00HighView Rating Details
9/18/2017Deutsche BankReiterated RatingBuy$255.00LowView Rating Details
7/14/2017Jefferies GroupReiterated RatingBuy$275.00LowView Rating Details
10/12/2016CL KingInitiated CoverageBuy$180.00N/AView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Bio-Rad Laboratories (NYSE:BIO) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE BIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018$1.26N/AView Earnings Details
11/2/2017Q3 2017$0.54$0.91$507.99 million$535.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.63$0.58$515.04 million$504.67 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.27$0.41$477.76 million$500.05 millionViewListenView Earnings Details
2/23/2017Q416$1.03($0.70)$574.40 million$571.45 millionViewN/AView Earnings Details
11/1/2016Q316$0.51$0.62$480.60 million$508.75 millionViewN/AView Earnings Details
8/3/2016Q2$1.13$0.61$497.80 million$516.80 millionViewN/AView Earnings Details
5/5/2016Q1$0.60$0.42$463.90 million$471.20 millionViewN/AView Earnings Details
2/25/2016Q415$1.27$1.68$570.80 million$570.56 millionViewListenView Earnings Details
11/3/2015Q315$0.54$0.59$495.55 million$469.96 millionViewN/AView Earnings Details
8/6/2015Q215$0.78$0.97$494.85 million$506.10 millionViewN/AView Earnings Details
5/5/2015Q115$0.33$0.61$474.60 million$472.80 millionViewN/AView Earnings Details
2/26/2015Q414$1.18$1.34$593.41 million$598.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.86$0.39$525.40 million$530.64 millionViewN/AView Earnings Details
8/5/2014Q214$0.95$1.09$537.58 million$536.80 millionViewN/AView Earnings Details
5/6/2014Q114$0.80$0.23$515.00 million$509.30 millionViewN/AView Earnings Details
2/27/2014Q413$1.42$1.04$586.67 million$602.60 millionViewListenView Earnings Details
11/7/2013Q313$0.91($0.25)$529.02 million$505.10 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.25$1.20$532.60 million$525.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.03$0.68$506.34 million$499.70 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.33$1.65$558.68 million$573.80 millionViewN/AView Earnings Details
11/6/2012Q312$1.14$1.48$507.79 million$498.70 millionViewN/AView Earnings Details
8/7/2012$1.19$1.69ViewN/AView Earnings Details
5/1/2012$1.02$1.09ViewN/AView Earnings Details
2/23/2012$1.67$2.08ViewN/AView Earnings Details
11/1/2011$1.53$1.61ViewN/AView Earnings Details
8/2/2011$1.47$1.41ViewN/AView Earnings Details
5/3/2011$1.32$1.16ViewN/AView Earnings Details
2/24/2011$1.35$2.41ViewN/AView Earnings Details
11/2/2010Q3 2010$1.17$1.59ViewN/AView Earnings Details
8/3/2010Q2 2010$1.27$1.35ViewN/AView Earnings Details
5/4/2010Q1 2010$1.17$1.24ViewN/AView Earnings Details
2/24/2010Q4 2009$1.08$1.49ViewN/AView Earnings Details
11/3/2009Q3 2009$1.00$1.38ViewN/AView Earnings Details
8/4/2009Q2 2009$1.03$1.37ViewN/AView Earnings Details
5/5/2009Q1 2009$0.98$1.10ViewN/AView Earnings Details
2/26/2009Q4 2008$0.90$1.18ViewN/AView Earnings Details
11/6/2008Q3 2008$1.06$1.01ViewN/AView Earnings Details
8/5/2008Q2 2008$1.08$1.58ViewN/AView Earnings Details
5/6/2008Q1 2008$0.99$0.97ViewN/AView Earnings Details
2/28/2008Q4 2007$0.80$0.92ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bio-Rad Laboratories (NYSE:BIO) Earnings Estimates

2018 EPS Consensus Estimate: $4.76
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.04$1.04$1.04
Q2 20181$1.33$1.33$1.33
Q3 20181$1.05$1.05$1.05
Q4 20181$1.34$1.34$1.34
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Bio-Rad Laboratories (NYSE:BIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bio-Rad Laboratories (NYSE BIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.29%
Institutional Ownership Percentage: 63.92%
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE BIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Christine A TsingosCFOSell4,980$249.40$1,242,012.007,283View SEC Filing  
12/4/2017Michael CrowleyEVPSell1,000$258.39$258,390.002,492View SEC Filing  
11/30/2017James R. StarkVPSell746$270.51$201,800.46View SEC Filing  
11/14/2017Giovanni MagniEVPSell2,400$253.01$607,224.009,251View SEC Filing  
8/11/2017Michael CrowleyEVPSell700$215.91$151,137.002,060View SEC Filing  
3/7/2017Michael CrowleyEVPSell300$196.13$58,839.002,760View SEC Filing  
11/9/2016James R. StarkVPSell1,299$171.42$222,674.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bio-Rad Laboratories (NYSE BIO) News Headlines

Source:
DateHeadline
Bio-Rad Gains Additional U.S. FDA Clearances for Blood Typing Products, Expanding its Offering for the Blood Testing MarketBio-Rad Gains Additional U.S. FDA Clearances for Blood Typing Products, Expanding its Offering for the Blood Testing Market
finance.yahoo.com - January 22 at 5:59 PM
Abiomed Hits New 52-Week High: 3 Factors Driving the StockAbiomed Hits New 52-Week High: 3 Factors Driving the Stock
finance.yahoo.com - January 19 at 11:25 AM
Becton, Dickinson Completes Enrollment in Lutonix DCB TrialBecton, Dickinson Completes Enrollment in Lutonix DCB Trial
finance.yahoo.com - January 19 at 11:25 AM
BD's CE Mark and Check-Point's Screening Test to Fight CPOBD's CE Mark and Check-Point's Screening Test to Fight CPO
finance.yahoo.com - January 17 at 11:16 AM
Bio-Rad Laboratories, Inc. (BIO) Expected to Post Quarterly Sales of $617.23 MillionBio-Rad Laboratories, Inc. (BIO) Expected to Post Quarterly Sales of $617.23 Million
www.americanbankingnews.com - January 16 at 8:28 PM
CVS Health Grows on Pharmacy Services, Retail Remains a DragCVS Health Grows on Pharmacy Services, Retail Remains a Drag
finance.yahoo.com - January 16 at 11:25 AM
Baxter (BAX) Launches Arisure Closed System Transfer DeviceBaxter (BAX) Launches Arisure Closed System Transfer Device
finance.yahoo.com - January 15 at 11:05 AM
Bio-Rad Laboratories, Inc. (BIO) Expected to Announce Earnings of $1.27 Per ShareBio-Rad Laboratories, Inc. (BIO) Expected to Announce Earnings of $1.27 Per Share
www.americanbankingnews.com - January 14 at 3:30 AM
Integra LifeSciences Estimates Strong Revenue Figures for Q4Integra LifeSciences Estimates Strong Revenue Figures for Q4
finance.yahoo.com - January 12 at 11:17 AM
Stocks To Watch: Bio Rad Labs Sees RS Rating Jump To 81Stocks To Watch: Bio Rad Labs Sees RS Rating Jump To 81
finance.yahoo.com - January 10 at 11:22 AM
CVS Healths (CVS) Outlook for 2018 Cheered by InvestorsCVS Health's (CVS) Outlook for 2018 Cheered by Investors
www.nasdaq.com - January 5 at 3:43 PM
Comparing Bio-Rad Laboratories (BIO) and SurModics (SRDX)Comparing Bio-Rad Laboratories (BIO) and SurModics (SRDX)
www.americanbankingnews.com - January 4 at 3:28 PM
Bio-Rad Laboratories, Inc. (BIO) Receives Average Recommendation of "Buy" from BrokeragesBio-Rad Laboratories, Inc. (BIO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 4 at 2:26 AM
Financial Survey: Cardiovascular Systems (CSII) vs. Bio-Rad Laboratories (BIO)Financial Survey: Cardiovascular Systems (CSII) vs. Bio-Rad Laboratories (BIO)
www.americanbankingnews.com - January 1 at 5:32 AM
$617.23 Million in Sales Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter$617.23 Million in Sales Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter
www.americanbankingnews.com - December 30 at 10:14 AM
 Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) to Announce $1.27 Earnings Per Share Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) to Announce $1.27 Earnings Per Share
www.americanbankingnews.com - December 28 at 8:18 AM
PRA Health (PRAH) Hits 52-Week High on Multiple PositivesPRA Health (PRAH) Hits 52-Week High on Multiple Positives
finance.yahoo.com - December 26 at 12:39 PM
4 MedTech Stocks to Explode in 20184 MedTech Stocks to Explode in 2018
finance.yahoo.com - December 22 at 4:51 PM
ETFs with exposure to Bio-Rad Laboratories, Inc. : December 21, 2017ETFs with exposure to Bio-Rad Laboratories, Inc. : December 21, 2017
finance.yahoo.com - December 21 at 11:23 AM
Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : December 21, 2017Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : December 21, 2017
finance.yahoo.com - December 21 at 11:23 AM
GW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in SessionGW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session
finance.yahoo.com - December 15 at 11:51 AM
Bio-Rad Laboratories, Inc. (BIO) CFO Christine A. Tsingos Sells 4,980 SharesBio-Rad Laboratories, Inc. (BIO) CFO Christine A. Tsingos Sells 4,980 Shares
www.americanbankingnews.com - December 14 at 8:52 PM
Protein Expression Market, 2023Protein Expression Market, 2023
finance.yahoo.com - December 14 at 3:44 PM
Bio-Rad Laboratories (BIO) Rating Increased to Strong-Buy at Zacks Investment ResearchBio-Rad Laboratories (BIO) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - December 13 at 4:46 PM
Global Protein Expression Market 2016-2023: Market is Expected to Grow from $1.4 Billion to $3.0 BillionGlobal Protein Expression Market 2016-2023: Market is Expected to Grow from $1.4 Billion to $3.0 Billion
www.benzinga.com - December 13 at 3:44 PM
Zacks: Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Post Quarterly Sales of $617.23 MillionZacks: Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Post Quarterly Sales of $617.23 Million
www.americanbankingnews.com - December 12 at 1:56 AM
 Analysts Expect Bio-Rad Laboratories, Inc. (BIO) Will Announce Earnings of $1.27 Per Share Analysts Expect Bio-Rad Laboratories, Inc. (BIO) Will Announce Earnings of $1.27 Per Share
www.americanbankingnews.com - December 10 at 11:32 PM
Bio-Rad Laboratories, Inc. (BIO) Receives Consensus Recommendation of "Buy" from AnalystsBio-Rad Laboratories, Inc. (BIO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 10 at 1:52 AM
ETFs with exposure to Bio-Rad Laboratories, Inc. : December 7, 2017ETFs with exposure to Bio-Rad Laboratories, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 3:47 PM
Outstanding Measures for Earnings Momentum Keep Bio Rad Laboratories (BIO) a Strong BuyOutstanding Measures for Earnings Momentum Keep Bio Rad Laboratories (BIO) a Strong Buy
investorplace.com - December 7 at 12:23 PM
Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 1:00 PM
Michael Crowley Sells 1,000 Shares of Bio-Rad Laboratories, Inc. (BIO) StockMichael Crowley Sells 1,000 Shares of Bio-Rad Laboratories, Inc. (BIO) Stock
www.americanbankingnews.com - December 4 at 9:02 PM
Bio-Rad (BIO) at a 52-Week High: Whats Driving the Stock?Bio-Rad (BIO) at a 52-Week High: What's Driving the Stock?
www.zacks.com - December 1 at 6:30 PM
Bio-Rad Laboratories, Inc. (BIO) VP James R. Stark Sells 746 SharesBio-Rad Laboratories, Inc. (BIO) VP James R. Stark Sells 746 Shares
www.americanbankingnews.com - November 30 at 8:22 PM
Best-in-Class Metrics for Earnings Growth Keep Bio Rad Laboratories (BIO) a Strong BuyBest-in-Class Metrics for Earnings Growth Keep Bio Rad Laboratories (BIO) a Strong Buy
investorplace.com - November 30 at 12:04 PM
Bio-Rad Laboratories (BIO) Earns "Outperform" Rating from Wells Fargo & CompanyBio-Rad Laboratories (BIO) Earns "Outperform" Rating from Wells Fargo & Company
www.americanbankingnews.com - November 29 at 7:30 PM
Bio-Rad Laboratories (BIO) to Repurchase $250.00 million in  Outstanding Stock Bio-Rad Laboratories (BIO) to Repurchase $250.00 million in Outstanding Stock
www.americanbankingnews.com - November 29 at 11:10 AM
BRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase ProgramBRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase Program
www.reuters.com - November 28 at 3:39 PM
Bio-Rad Labs (BIO) Announces $250M Stock BuybackBio-Rad Labs (BIO) Announces $250M Stock Buyback
www.streetinsider.com - November 28 at 3:39 PM
Bio-Rad Authorizes New $250 Million Share Repurchase ProgramBio-Rad Authorizes New $250 Million Share Repurchase Program
finance.yahoo.com - November 28 at 3:39 PM
Comparing Bio-Rad Laboratories (BIO) & ICU Medical (ICUI)Comparing Bio-Rad Laboratories (BIO) & ICU Medical (ICUI)
www.americanbankingnews.com - November 26 at 9:40 AM
Bio Rad Laboratories (BIO) a Strong Buy on High-Level Quant ScoreBio Rad Laboratories (BIO) a Strong Buy on High-Level Quant Score
investorplace.com - November 23 at 12:21 PM
$1.27 EPS Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter$1.27 EPS Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter
www.americanbankingnews.com - November 23 at 1:26 AM
Global Immunoassay Reagents and Devices Market Expected To Be Worth US$ 26.00 Billion By 2022Global Immunoassay Reagents and Devices Market Expected To Be Worth US$ 26.00 Billion By 2022
www.marketwatch.com - November 22 at 10:12 PM
Bio-Rad to Webcast Investor Day 2017Bio-Rad to Webcast Investor Day 2017
finance.yahoo.com - November 21 at 11:21 PM
Global high throughput screening market analysis and forecast to 2022 made available by Meticulous Research™Global high throughput screening market analysis and forecast to 2022 made available by Meticulous Research™
globenewswire.com - November 21 at 3:29 PM
Single Cell Analysis Market to Grow Owing to Rising Prevalence of Life Threatening Diseases Till 2024 | Million InsightsSingle Cell Analysis Market to Grow Owing to Rising Prevalence of Life Threatening Diseases Till 2024 | Million Insights
www.marketwatch.com - November 21 at 3:54 AM
Bio-Rad Laboratories, Inc. (BIO) Upgraded to B- by TheStreetBio-Rad Laboratories, Inc. (BIO) Upgraded to B- by TheStreet
www.americanbankingnews.com - November 19 at 8:16 PM
ETFs with exposure to Bio-Rad Laboratories, Inc. : November 17, 2017ETFs with exposure to Bio-Rad Laboratories, Inc. : November 17, 2017
finance.yahoo.com - November 17 at 4:10 PM
Bio-Rad Laboratories, Inc. (BIO) EVP Sells $607,224.00 in StockBio-Rad Laboratories, Inc. (BIO) EVP Sells $607,224.00 in Stock
www.americanbankingnews.com - November 15 at 8:20 PM

SEC Filings

Bio-Rad Laboratories (NYSE:BIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bio-Rad Laboratories (NYSE:BIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bio-Rad Laboratories (NYSE BIO) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.